Biogen Inc. and C4 Therapeutics Inc. have synthesized proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to an IL-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.